Literature DB >> 9811346

Pathological findings in human autoimmune lymphoproliferative syndrome.

M S Lim1, S E Straus, J K Dale, T A Fleisher, M Stetler-Stevenson, W Strober, M C Sneller, J M Puck, M J Lenardo, K S Elenitoba-Johnson, A Y Lin, M Raffeld, E S Jaffe.   

Abstract

The defects in lymphocyte apoptosis that underlie the autoimmune lymphoproliferative syndrome (ALPS) are usually attributable to inherited mutations of the CD95 (Fas) gene. In this report, we present the histopathological and immunophenotypic features seen in the lymph nodes (n = 16), peripheral blood (n = 10), bone marrow (n = 2), spleen (n = 3), and liver (n = 2) from 10 patients with ALPS. Lymph nodes showed marked paracortical hyperplasia. Interfollicular areas were expanded and populated by T cell receptor-alphabeta CD3+ CD4-CD8- (double-negative, DN) T cells that were negative for CD45RO. CD45RA+ T cells were increased in all cases studied. The paracortical infiltrate was a result of both reduced apoptosis and increased proliferation, as measured by in situ detection of DNA fragmentation and staining with MIB-1, respectively. The paracortical proliferation may be extensive enough to suggest a diagnosis of malignant lymphoma. Many of the paracortical lymphocytes expressed markers associated with cytotoxicity, such as perforin, TIA-1, and CD57. CD25 was negative. In addition, most lymph nodes exhibited florid follicular hyperplasia, often with focal progressive transformation of germinal centers; in some cases, follicular involution was seen. A polyclonal plasmacytosis also was present. The spleens were markedly enlarged, more than 10 times normal size. There was expansion of both white pulp and red pulp, with increased DN T cells. DN T cells also were observed in liver biopsies exhibiting portal triaditis. In the peripheral blood, the T cells showed increased expression of HLA-DR and CD57 but not CD25. CD45RA+ T cells were increased in the four cases studied. Polyclonal B cell lymphocytosis with expansion of CD5+ B cells was a characteristic finding. Taken together, the histopathological and immunophenotypic findings, particularly in lymph nodes and peripheral blood, are sufficiently distinctive to suggest a diagnosis of ALPS. Of note, two affected family members of one proband developed lymphoma (T-cell-rich B-cell lymphoma and nodular lymphocyte predominance Hodgkin's disease, respectively).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811346      PMCID: PMC1853411          DOI: 10.1016/S0002-9440(10)65742-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  Epstein-Barr virus strain type and latent membrane protein 1 gene deletions in lymphomas in patients with rheumatic diseases.

Authors:  Y Natkunam; K S Elenitoba-Johnson; D W Kingma; O W Kamel
Journal:  Arthritis Rheum       Date:  1997-06

2.  Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.

Authors:  J Drappa; A K Vaishnaw; K E Sullivan; J L Chu; K B Elkon
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

Review 3.  Basic biology of autoimmune phenomena in chronic lymphocytic leukemia.

Authors:  O Pritsch; K Maloum; G Dighiero
Journal:  Semin Oncol       Date:  1998-02       Impact factor: 4.929

4.  Chronic lymphadenopathy simulating malignant lymphoma.

Authors:  V C Canale; C H Smith
Journal:  J Pediatr       Date:  1967-06       Impact factor: 4.406

5.  Marginal zone B-cell lymphoma with monocytoid B-cell lymphocytes in pediatric patients without immunodeficiency. A report of two cases.

Authors:  K S Elenitoba-Johnson; S Kumar; M S Lim; D W Kingma; M Raffeld; E S Jaffe
Journal:  Am J Clin Pathol       Date:  1997-01       Impact factor: 2.493

6.  Enhanced and accelerated lymphoproliferation in Fas-null mice.

Authors:  M Adachi; S Suematsu; T Suda; D Watanabe; H Fukuyama; J Ogasawara; T Tanaka; N Yoshida; S Nagata
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

7.  Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.

Authors:  M C Sneller; J Wang; J K Dale; W Strober; L A Middelton; Y Choi; T A Fleisher; M S Lim; E S Jaffe; J M Puck; M J Lenardo; S E Straus
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

8.  Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity.

Authors:  I J Fuss; W Strober; J K Dale; S Fritz; G R Pearlstein; J M Puck; M J Lenardo; S E Straus
Journal:  J Immunol       Date:  1997-02-15       Impact factor: 5.422

9.  Clinical, immunological, and pathological consequences of Fas-deficient conditions.

Authors:  F Le Deist; J F Emile; F Rieux-Laucat; M Benkerrou; I Roberts; N Brousse; A Fischer
Journal:  Lancet       Date:  1996-09-14       Impact factor: 79.321

10.  Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation.

Authors:  U Dianzani; M Bragardo; D DiFranco; C Alliaudi; P Scagni; D Buonfiglio; V Redoglia; S Bonissoni; A Correra; I Dianzani; U Ramenghi
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

View more
  39 in total

1.  Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop.

Authors:  Joao B Oliveira; Jack J Bleesing; Umberto Dianzani; Thomas A Fleisher; Elaine S Jaffe; Michael J Lenardo; Frederic Rieux-Laucat; Richard M Siegel; Helen C Su; David T Teachey; V Koneti Rao
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma.

Authors:  Ewerton M Maggio; Anke Van Den Berg; Debora de Jong; Arjan Diepstra; Sibrand Poppema
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

3.  [Inflammatory reactions of the spleen].

Authors:  T Rüdiger; M Hartmann; H K Müller-Hermelink; A Marx
Journal:  Pathologe       Date:  2008-03       Impact factor: 1.011

Review 4.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

5.  ALPS-ten lessons from an international workshop on a genetic disease of apoptosis.

Authors:  Michael J Lenardo; João B Oliveira; Lixin Zheng; V Koneti Rao
Journal:  Immunity       Date:  2010-03-26       Impact factor: 31.745

6.  T and B cell clonal expansion in Ras-associated lymphoproliferative disease (RALD) as revealed by next-generation sequencing.

Authors:  S Levy-Mendelovich; A Lev; E Rechavi; O Barel; H Golan; B Bielorai; Y Neumann; A J Simon; R Somech
Journal:  Clin Exp Immunol       Date:  2017-06-05       Impact factor: 4.330

7.  Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).

Authors:  V Koneti Rao; Susan Price; Katie Perkins; Patricia Aldridge; Jean Tretler; Joie Davis; Janet K Dale; Fred Gill; Kip R Hartman; Linda C Stork; David J Gnarra; Lakshmanan Krishnamurti; Peter E Newburger; Jennifer Puck; Thomas Fleisher
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

8.  Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).

Authors:  Kennichi C Dowdell; Lesley Pesnicak; Victoria Hoffmann; Kenneth Steadman; Alan T Remaley; Jeffrey I Cohen; Stephen E Straus; V Koneti Rao
Journal:  Exp Hematol       Date:  2009-02-12       Impact factor: 3.084

Review 9.  Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).

Authors:  David T Teachey; Alix E Seif; Stephan A Grupp
Journal:  Br J Haematol       Date:  2009-11-23       Impact factor: 6.998

10.  Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.

Authors:  Marta Christensson; Erna Pettersson; Kjell Eneslätt; Birger Christensson; Johan Bratt; Solbritt Rantapää-Dahlqvist; Karl-Gösta Sundqvist
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.